Alzheimer’s

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

This week in drug discovery (27 Nov – 1 Dec) 

News round-up for 27 November – 1 December by DDW Digital Content Editor Diana Spencer. The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and… Read More

#News

#Alzheimer's #Computer modelling #Neurodegenerative disorders #Neuroscience #Penn State University #Predictive diagnostics

Mathematical model can speed up Alzheimer’s drug development

Researchers have created a mathematical model that can accurately predict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. According to the model, the disease onset and rate of progression varies on a case by case basis, meaning… Read More

#Editor's Choice #News

#Alzheimer's #Drug discovery #Neurology #Stem cells

bit.bio launches stem cell line for neuro research and screening  

Biotechnology company bit.bio has launched a range of immune cells to provide researchers with a consistently functional and rapid human in vitro model for the study of neuroinflammation and neurodegenerative diseases.  The company’s ioMicroglia cell range is designed to recapitulate key human microglia functions and… Read More

#News

The microbiome
#Alzheimer's #Antibodies #Cancer #Covid-19 #Rare disease #Therapeutic Antibodies

Which diseases will benefit from therapeutic antibody development?

Listen to this article on the DDW Podcast: DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. Alongside surgery, radiation and chemotherapy, antibody-based immunotherapy… Read More

#Exclusive Content

Blood samples in lab
#Alzheimer's #Biomarkers #Diagnostics #Neurodegenerative disorders #PharmaKure

Novel blood test identifies Alzheimer’s risk with 97% accuracy

A new blood test has been shown to identify biomarkers for Alzheimer’s disease, providing an early warning of cognitive decline. Early results from PharmaKure, a pharmaceutical company spun out from The University of Manchester, UK, shows a novel whole blood test (ALZmetrix) developed by the company… Read More

#News #Trending News

MRI of the brain
#Alzheimer's #AstronauTx #Financing #Neurodegenerative disorders #University College London

UCL spinout raises £48m funding for new approach to Alzheimer’s

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer's Research UK UCL Drug Discovery Institute (UCL DDI). Protoplasmic astrocytes play… Read More

#Business & Investment #News

Human brain
#Alzheimer's #Artificial intelligence (AI) #Insilico Medicine #Neurodegenerative disorders #Omics #University of Cambridge

Study finds new therapeutic targets for neurodegenerative disease

AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method… Read More

#Editor's Choice #News

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neurology

Study opens up new therapeutic pathways in Alzheimer’s disease 

A research team from VIB-KU Leuven and the UK Dementia Research Institute has discovered how neurons die in Alzheimer’s disease, opening new pathways for potential future treatments.  A new research paper published in Science illustrates how neurons initiate a programmed form of cell death, known… Read More

#News

Stephen Back and Philip Adeniyi, OHSU School of Medicine
#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience #Oregon Health & Science University

Scientists discover new target for Alzheimer’s drugs

Researchers have discovered a new avenue of cell death in Alzheimer’s disease and vascular dementia. A new study, led by scientists at Oregon Health & Science University (OHSU), has revealed that a form of cell death known as ferroptosis – caused by a build-up of iron… Read More

#Editor's Choice #News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week reflects the high level of interest and investment in… Read More

#News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

This week in drug discovery (21-25 August)  

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and… Read More

#News

Doctor administering a vaccine to patient
#Alzheimer's #Immune system #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience

Routine vaccines as effective as antibodies against Alzheimer’s

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus… Read More

#News #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #epilepsy #Neuroinflammation #Parkinson's #Phase I trial #Ventus Therapeutics

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Based on the safety margins demonstrated in IND-enabling studies, the Phase I trial is designed to fully explore VENT-02’s pharmacodynamics, safety, and… Read More

#News

CT scans of the brain
#Alzheimer's #Immunotherapy #Neurodegenerative disorders #Phase II trial #Vaxxinity

Alzheimer’s immunotherapy offers safer, cheaper alternative

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies. Vaxxinity published the Phase IIa clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating… Read More

#Editor's Choice #News

Ozempic Insulin injection pen
#Alzheimer's #Dementia #Nicotine addiction #Novo Nordisk #Type 2 diabetes

Could GLP-1 receptor agonists like Ozempic treat addiction and dementia?

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk… Read More

#News #Trending News

Dementia
#Alzheimer's #Dementia #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Oligomerix

Preclinical data supports new approach to Alzheimer’s disease

Preclinical data has demonstrated that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, the company Oligomerix announced the first-in-human dosing of OLX-07010 in a Phase Ia clinical… Read More

#Editor's Choice #News